Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD EMPA-REG OUTCOME - Empagliflozin lowered CV events in T2DM + ASCVD; signal for SGLT2i in HF and CKD. CANVAS - Canagliflozin lowered CV events in T2DM + ASCVD or ASCVD risk; signal for SGLT2i in HF and CKD. DECLARE-TIMI 58 - Dapagliflozin lowered CV death or HHF, but had no effect on MACE, in T2DM + ASCVD or ASCVD risk. CREDENCE - Canagliflozin lowered adverse kidney events in CKD + T2DM; first renal outcomes trial in SGLT2i. DAPA-CKD - Dapagliflozin lowered adverse kidney events for patients with CKD, with or without T2DM. DAPA-HF - Dapagliflozin improved HF outcomes in HFrEF on GDMT, with or without T2DM. EMPEROR-REDUCED - Empagliflozin improved HF outcomes in HFrEF on GDMT, with or without T2DM. by Dr. Jefferson Triozzi @nepherson and Dr. Tony McClafferty @mcclaffertyMD #SGLT2 #inhibitors #EBM #trial #visualabstract #table #CVD #CKD
